NCT04273217View on ClinicalTrials.gov

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

AV-1

Single dose, administered by IV infusion (volume: 250 mL)

DRUG

Placebo

0.9% sterile saline. Administered by IV infusion (volume: 250 mL)

Trial Locations (1)

78744

PPD Austin Clinic, 7551 Metro Center Drive, Suite 200, Austin

Sponsors

Lead Sponsor

AbViro LLC
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

AbViro LLC

INDUSTRY

NCT04273217 - A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers | Biotech Hunter | Biotech Hunter